XOLAIR: payments to doctors
Payments that named XOLAIR as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $31.4M
- Providers
- 17,890
- Transactions
- 133,042
- Average per transaction
- $236
The per-transaction average — $236 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 17,890 providers the average total is $1,756, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Genentech, Inc. | $22,122,046 | 70.4% |
| Genentech USA, Inc. | $6,922,386 | 22.0% |
| Novartis | $2,144,716 | 6.8% |
| F. Hoffmann-la Roche AG | $221,761 | 0.7% |
| Novartis Pharma AG | $7,069 | 0.0% |